Day One Biopharmaceuticals
DAWN
DAWN was delisted on the 22nd of April, 2026.
149 hedge funds and large institutions have $1.2B invested in Day One Biopharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 49 increasing their positions, 44 reducing their positions, and 16 closing their positions.
63% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 16
50% more funds holding in top 10
Funds holding in top 10: 4 → 6 (+2)
11% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 44
7% more funds holding
Funds holding: 139 → 149 (+10)
7% more capital invested
Capital invested by funds: $1.12B → $1.2B (+$80.1M)
1% more call options, than puts
Call options by funds: $1.31M | Put options by funds: $1.29M
5.03% less ownership
Funds ownership: 88.36% → 83.33% (-5%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MC
Maverick Capital
Dallas,
Texas
|
+$18.8M |
| 2 |
ECM
Estuary Capital Management
Wayzata,
Minnesota
|
+$10.9M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$6.53M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
+$5.03M |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$3.53M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
B
Braidwell
Stamford,
Connecticut
|
-$30.6M |
| 2 |
AVLSA
Atlas Venture Life Science Advisors
Cambridge,
Massachusetts
|
-$17.6M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
-$14.6M |
| 4 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$14.2M |
| 5 |
State Street
Boston,
Massachusetts
|
-$7.26M |
DAWN Hedge Fund Activity: Q1 2024 in Review
149 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Day One Biopharmaceuticals (DAWN) for Q1 2024, worth a combined $1.2B — up 7.1% from $1.12B a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new DAWN positions and 16 closed out — a net gain of 10 holders — while 49 added to existing stakes and 44 trimmed.
The largest buyer was Maverick Capital, opening a new position worth an estimated $18.8M. The largest seller was Braidwell, cutting an estimated $30.6M.
- 149 institutional investors held Day One Biopharmaceuticals (DAWN) as of Q1 2024, up from 139 in Q4 2023.
- Funds reported $1.2B of Day One Biopharmaceuticals stock for Q1 2024, up 7.1% quarter-over-quarter.
- 26 funds opened new Day One Biopharmaceuticals positions in Q1 2024 and 16 closed out, a net change of +10 holders.
- The largest Day One Biopharmaceuticals buyer in Q1 2024 was Maverick Capital, an estimated $18.8M added.
- The largest Day One Biopharmaceuticals seller in Q1 2024 was Braidwell, an estimated $30.6M sold.
Based on aggregated 13F filings for Q1 2024.